Drug intelligence / Profile preview

Glucosanol

Development stage: Preclinical
Lead developer: InQpharm
Administration: Oral

Overview

Glucosanol, also known as Phaseolamin, is a dietary supplement developed by InQpharm Group. It functions as a proteinaceous inhibitor of alpha-amylase, an enzyme responsible for breaking down complex carbohydrates. By inhibiting alpha-amylase, Glucosanol reduces the digestion and absorption of carbohydrates in the small intestine, thereby aiding in weight loss and the reduction of post-prandial glucose levels. It is derived from white kidney beans.

Brand names: Glucosanol
Other names: Phaseolamin

Targets

AMY (Pancreatic alpha-amylase)

Beyond the preview

Go deeper on Glucosanol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glucosanol.

Explore the full profile